Annexon Expands Board of Directors with Appointment of Commercial Executive William BJ Jones
| ANNX Stock | USD 3.84 0.20 4.95% |
Slightly above 63% of Annexon's investor base is looking to short. The analysis of the overall investor sentiment regarding Annexon suggests that many traders are alarmed. Annexon's investing sentiment can be driven by a variety of factors including economic data, Annexon's earnings reports, geopolitical events, and overall market trends.
Annexon |
Seasoned biotechnology industry leadership spanning three decades across U.S. and global commercial operationsBRISBANE, Calif., Jan. 10, 2025 -- Annexon, Inc. , a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the appointment of William BJ Jones to its board of directors. Mr. Jones brings 3
Read at finance.yahoo.com
 |
Annexon Fundamental Analysis
We analyze Annexon's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Annexon using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Annexon based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Annexon is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Annexon Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Annexon stock to make a market-neutral strategy. Peer analysis of Annexon could also be used in its relative valuation, which is a method of valuing Annexon by comparing valuation metrics with similar companies.
Peers
Annexon Related Equities
| ZURA | Zura Bio | 6.82 | ||||
| XFOR | X4 Pharmaceuticals | 6.08 | ||||
| AMLX | Amylyx Pharmaceuticals | 3.99 | ||||
| INAB | In8bio | 2.32 | ||||
| GPCR | Structure Therapeutics | 1.15 | ||||
| BPMC | Blueprint Medicines | 1.33 | ||||
| INZY | Inozyme Pharma | 1.37 | ||||
| IMMX | Immix Biopharma | 1.52 | ||||
| RLAY | Relay Therapeutics | 1.54 | ||||
| RCUS | Arcus Biosciences | 3.59 | ||||
| DAWN | Day One | 3.81 | ||||
| CGEM | Cullinan Oncology | 3.83 | ||||
| ABOS | Acumen Pharmaceuticals | 3.85 | ||||
| WVE | Wave Life | 4.06 | ||||
| HEPA | Hepion Pharmaceuticals | 5.53 |
Additional Tools for Annexon Stock Analysis
When running Annexon's price analysis, check to measure Annexon's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annexon is operating at the current time. Most of Annexon's value examination focuses on studying past and present price action to predict the probability of Annexon's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annexon's price. Additionally, you may evaluate how the addition of Annexon to your portfolios can decrease your overall portfolio volatility.